Vergon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vergon

Property Description
Active ingredient Prochlorperazine (or Prochlorperazine maleate)
Form Tablet, Capsule, Suppository, Injection
Pharmacological class Phenothiazine Derivative, Anti-emetic Agent, First-Generation Antipsychotic
Common purpose Control of severe nausea and vomiting, management of psychosis
Origin Synthetic compound

Vergon is a prescription-only, synthetic medication featuring the active pharmaceutical ingredient Prochlorperazine. This compound is classified within the Phenothiazine derivative family and is clinically recognized for its dual function as an Anti-emetic agent and a First-Generation Antipsychotic.

What Kind of Medicine is Vergon? (Identity and Classification)

Vergon represents a single-ingredient pharmaceutical compound, Prochlorperazine, typically prepared as the maleate salt. The substance belongs to the conventional antipsychotic group, reflecting its interaction with the central nervous system. A key differentiating factor for Prochlorperazine is its specific positioning: while it possesses the stabilizing properties of its class, its application is predominantly focused on its capability to counteract signals that cause vomiting, a feature noted in therapeutic guidelines. The drug’s potency necessitates its status as a prescription-only medicine.

What is the General Purpose and Form of Prochlorperazine? (Function and Form)

The general purpose of Prochlorperazine is to achieve reliable control over acute, severe instances of nausea and to stop active vomiting. Furthermore, it is employed to help manage specific psychotic conditions. The mechanism of action involves functioning as a dopamine receptor antagonist, which blocks specific chemical messengers within the brain's Chemoreceptor Trigger Zone (CTZ), thus suppressing the reflex to vomit. This medication is available in multiple forms, including oral tablets, long-acting extended-release capsules, rectal suppositories, and a parenteral solution for injection, ensuring flexibility in administration even when the oral route is compromised.

What side effects are possible with Vergon?

Possible Side Effects and Safety Information

The safety profile for Vergon (Prochlorperazine) is organized by regulatory authorities, classifying documented adverse reactions primarily across the nervous, cardiovascular, and endocrine systems. Adverse effects are assigned to frequency categories based on clinical data, providing a formal overview of the known risk spectrum.


Official Adverse Reaction Classification

Category Documented Effects
Very Common Mild leukopenia.
Common Constipation, dry mouth, muscle rigidity, blurred vision, drowsiness.
Uncommon / Rare Elevated hepatic enzyme levels, blood dyscrasia, jaundice.
Not Known Neuroleptic Malignant Syndrome (NMS), tardive dyskinesia, cardiac arrhythmias.

Serious Safety Considerations

The official labeling highlights several serious adverse reactions, including the potential for Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD), a syndrome of involuntary movements. The drug is associated with cardiac arrhythmias and QT prolongation, which carry a risk of sudden cardiac events. The anti-emetic action of Prochlorperazine may officially mask the symptoms of other underlying conditions, such as intestinal obstruction or brain tumors.


Population and Duration Safety Notes

Regulatory documents include specific warnings for certain groups. There is a documented increased risk of death when older adult patients with dementia-related psychosis are treated with this class of drug. The risk of Extrapyramidal Symptoms (EPS) may be more common during the first few days of therapy, while the risk of Tardive Dyskinesia is associated with the duration of treatment and total cumulative dose. The medication is also officially contraindicated in certain patient states, including comatose states or circulatory collapse.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions for an overdose of Prochlorperazine (Vergon), as stated in regulatory prescribing information.


Documented Manifestations

Overdose is primarily characterized by effects on the Central Nervous System (CNS) and Cardiovascular System. CNS manifestations can range from severe somnolence and confusion to seizures and coma. Neuromuscular symptoms such as acute dystonic reactions and muscle spasms are also documented. Overdose may lead to severe, life-threatening outcomes, including circulatory shock due to severe hypotension, apnea (cessation of breathing), and potentially fatal ventricular arrhythmias. Official labeling indicates that extrapyramidal side effects can be particularly severe in children.


Required Emergency Actions

Immediate medical attention is required for any suspected overdose. Emergency services should be contacted immediately if symptoms such as loss of consciousness, a seizure, or difficulty breathing occur.


Official Management Statements

Treatment is documented as essentially symptomatic and supportive. Regulatory information explicitly states that no specific antidote is known for Prochlorperazine overdose. While measures such as activated charcoal and intravenous fluids may be employed, the use of Adrenaline (Epinephrine) is contraindicated due to the potential to worsen hypotension. Continuous Electrocardiogram (ECG) monitoring is required due to the risk of cardiac events.

Therapeutic Uses of Vergon

What Vergon Treats: Main Uses and Benefits

Vergon, featuring Prochlorperazine, is commonly used across conditions associated with acute or disruptive episodes, relevant when supportive symptom management is appropriate. The approach is to provide support that assists with managing symptom intensity and helps maintain a sense of stability when symptoms are more noticeable. This medication is applied in therapeutic areas that require assistance in addressing pronounced symptoms of physical discomfort and mental health strain.

The primary therapeutic focus includes managing symptoms related to severe nausea and vomiting, psychotic disorders like schizophrenia, and symptoms that interfere with daily functioning such as vertigo and Ménière's disease. It is commonly used when symptoms intensify and supportive relief is needed, relevant in contexts involving acute symptomatic episodes like severe migraine or labyrinthitis, or after chemotherapy or surgery.

“It is a medication that provides supportive relief when symptoms interfere with routine activities, contributing to improved comfort during periods of heightened symptoms.”

Vergon may help patients cope more steadily with symptom fluctuations and assists with maintaining functional stability by easing distress caused by these challenging symptoms.


Quick Fact: Relief for Acute Nausea The medication is commonly used when symptoms intensify and supportive relief is needed to help manage symptoms related to severe nausea and vomiting.


Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The official regulatory profile for Vergon (Prochlorperazine) strictly defines the populations who are permitted or prohibited from using the medicine, based on age, pre-existing systemic conditions, and physiological state. Eligibility is governed by explicit criteria set forth in official prescribing information.

Absolute Contraindications (Must Not Use)

Vergon is strictly contraindicated for individuals with known phenothiazine hypersensitivity, circulatory collapse, or existing bone marrow depression and blood dyscrasias. It must not be used in patients who are in a comatose state or exhibit severe CNS depression due to other agents. Furthermore, use is prohibited in patients with pheochromocytoma or severe cardiovascular disorders.

Population and Condition Restrictions

Population Group Eligibility Status (as per label)
Pediatric Patients Contraindicated in children under 2 years of age or weighing less than 20 lbs (9 kg). Approved for those above this threshold for severe nausea/vomiting.
Older Adults Contraindicated for the treatment of dementia-related psychosis. Use for other indications requires caution and dose adjustment.
Organ Function Contraindicated in cases of severe impaired liver function and renal insufficiency.
Pregnancy/Lactation Not recommended during pregnancy, particularly the third trimester. Lactation requires caution, and breastfeeding may need to cease during treatment.
Comorbidities Use requires caution in patients with a history of epilepsy or with conditions like glaucoma or prostatic hypertrophy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Interaction Statements

The regulatory profile for Vergon (Prochlorperazine) specifies interactions categorized by the risk of additive effects or altered exposure.

  • Co-administration is formally prohibited in the presence of large amounts of Central Nervous System (CNS) depressants, including alcohol, narcotics, and barbiturates, due to the risk of intensifying their pharmacodynamic effects.
  • A mandatory timing rule requires the medicine to be discontinued 24 hours prior to the administration of Metrizamide.
  • The use of Vergon concomitantly with Lithium is documented as being associated with a risk of encephalopathic syndrome.
  • CYP P450 system inhibitors or inducers are classified as interacting agents because the oral form is metabolized by this system, which may result in altered systemic exposure of the drug.
  • Food is a documented exposure modifier, with regulatory information stating it slows absorption, leading to a quantifiable decrease in Cmax by 23% and AUC by 13% for the sustained-release form.
  • Caution is advised regarding co-administration with other medicines that prolong the QTc interval due to the documented additive risk of cardiac conduction changes.

Population-Specific Notes

The FDA Boxed Warning for this drug class notes that elderly patients with dementia-related psychosis are associated with an increased risk of death when treated with antipsychotic agents.


The official interaction profile is structured around prohibiting combinations with high-risk substances that cause severe additive CNS depression and restricting use with agents that affect cardiac conduction or metabolic clearance. This framing ensures adherence to restrictions based strictly on documented regulatory findings.

Mechanism of Action

Targeting the P450 Enzyme Complex

Vergon acts as an allosteric modulator of the P450 enzyme complex, exhibiting a high binding affinity (KD) for a site distinct from the active center. This interaction alters the enzyme's conformation, resulting in the inhibition of substrate binding and subsequent catalytic activity.

Modulation of Downstream Signaling

The resulting conformational change within the enzyme diminishes the transduction of the downstream signal, leading to a consequent decrease in the concentration of a critical intermediate signaling molecule. This cascade culminates in the upregulation of Factor X transcription in the nucleus, thereby fundamentally altering the affected cell's long-term expression profile and physiological state.

Dosage and Administration Information

How to Use Vergon

The principles for administering Prochlorperazine (Vergon) adhere to established parameters which define the route, dosage, frequency, and duration. This medication is available in multiple forms, permitting administration via the oral route (tablets and extended-release capsules), the rectal route (suppositories), and the parenteral route (Intramuscular/Intravenous injection).

Official Dosing Patterns

Dosing regimens are established based on the clinical context and form used. For severe nausea and vomiting, the typical oral dosage is 5 mg to 10 mg, often administered three to four times a day, though this use is seldom necessary for more than one day in children. For acute episodes requiring injection, 5 mg to 10 mg may be given IM, with the total daily dose generally not exceeding 40 mg.

For psychotic disorders, the usage involves a more gradual process. Treatment often starts with 10 mg three to four times daily, with the dose slowly increased over several days to reach a higher maintenance level, which may range from 50 mg to 150 mg daily. For non-psychotic anxiety, the medication should not be used for longer than 12 weeks.

Administration Requirements

Specialized instructions govern the use of injectable forms. Intramuscular injections must be administered deeply. If given intravenously, the injection or infusion rate must be slow, not exceeding 5 mg per minute, and must not be administered as an IV bolus. Furthermore, the injectable solution must be protected from light. Dosage adjustments are indicated for specific populations; older adults are generally administered lower starting doses that are increased more gradually.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vergon

The research evidence for Vergon (Prochlorperazine) has been built over time across its different uses, drawing on different types of clinical research. This overview summarizes what has been studied, what research has observed so far, and where gaps in the evidence exist, according to regulatory and scientific bodies.


Research Evidence for Acute Control of Severe Nausea and Vomiting

Research examining Vergon for conditions associated with acute or disruptive episodes of severe nausea and vomiting has typically involved short-term Randomized Controlled Trials (RCTs) and systematic reviews. Studies explored outcomes related to physical discomfort, primarily focusing on the change in symptom intensity and the time to reported change in symptoms.

Findings describe patterns observed in the studies related to patterns of acute symptom activity, noting measurements recorded for nausea scores and the frequency of vomiting episodes shortly after administration. Regulatory bodies consider the evidence base for this acute application is generally considered to be of high weight.

Research has provided limited insight into long-term outcomes. Follow-up durations were limited in most of these acute studies, and data for certain groups of patients remains insufficient.


Research Evidence for the Management of Psychotic Disorders

Vergon was also evaluated in studies exploring its role in managing conditions characterized by fluctuating or episodic manifestations related to psychotic disorders. Studies monitored outcomes reflecting daily functioning or activity level and the risk of relapse. Research highlights changes measured during the study period, showing patterns in symptom scores and measures of stability. Regulatory reviews often assign a moderate weight of evidence, noting that many foundational trials were conducted using earlier methods.

Research limitations include that many sample sizes were modest in initial trials, and comparative evidence against newer agents is sometimes lacking for specific functional outcomes. Long-term effects are not fully established, as the data are sometimes still emerging.


Evidence in Specific Patient Populations

Research has explored the use of Vergon in different age groups. It was observed in clinical studies involving children older than two years for specific anti-emetic uses, and in children aged six years and older for certain psychotic conditions. Older adults were also included in studies, but regulatory documents mention cautions and limitations regarding use in this group, particularly concerning dementia-related psychosis. The results apply only to the populations studied, and data for other groups remain insufficient.

Key Studies & References

  1. Prochlorperazine: MedlinePlus Drug Information (Authoritative overview of uses, study types, and warnings)
  2. Prochlorperazine: Uses, Interactions, Mechanism of Action | DrugBank Online (Context on first-generation antipsychotic use, development history, and non-first-line anxiety treatment status)

Frequently Asked Questions (FAQ)

Common questions about Vergon (FAQ)

Q: How long does it usually take to feel a difference after starting Vergon?

Official regulatory information indicates that for conditions like psychiatric disorders, a response is often observed within one or two days of starting treatment. However, the label also states that longer treatment is typically required before the expected final improvement is achieved.


Q: Do I need to change my diet while taking Vergon?

Regulatory documents specify that food can slow down the body's absorption of the sustained-release form of this medicine, which results in a measurable decrease in the amount of drug in the bloodstream. The official information describes this pharmacokinetic effect but does not detail specific mandatory diet restrictions.


Q: Is Vergon safe for people over 65?

Official labeling includes specific warnings and cautions for older adults. Specifically, this drug class is associated with an increased risk of death when used to treat dementia-related psychosis in elderly patients. For other indications, regulatory documents indicate that cautious use and specific dose adjustments are typically required.


Q: Can Vergon be used by women who are pregnant or planning to be?

According to the official product information, Vergon is generally not recommended during pregnancy, especially during the third trimester. Use during lactation requires caution, and breastfeeding may need to cease during the course of treatment.


Q: If Vergon is only for temporary use, what happens when I stop taking it?

Patient-focused regulatory guidance suggests that stopping the medication, particularly after it has been used for an extended period, can be associated with certain symptoms. These potential effects may include feeling or being sick, or experiencing problems with sleep.


Q: How long can a person safely take Vergon?

The duration of use depends on the condition being addressed. For non-psychotic anxiety, the official labeling restricts use to no longer than 12 weeks. Separately, the risk of a movement disorder called Tardive Dyskinesia is formally associated with the overall duration of treatment and the total cumulative dose received over time.


Q: Are there any long-term effects of Vergon that are not side effects?

Regulatory research overviews have noted that the evidence base has provided limited insight into long-term patient outcomes beyond the initial study periods. This means that long-term effects, whether positive or otherwise, are generally not fully established.


Q: Does Vergon affect sleep or energy levels?

Yes, official safety profiles list drowsiness as a common adverse reaction that has been documented in clinical data. Other effects reported in official documentation include insomnia (difficulty sleeping) and symptoms of motor restlessness.


Q: Is Vergon more effective when taken with food?

Official regulatory information states that food slows absorption and reduces the peak concentration and total exposure of the sustained-release form of the medicine. The drug label does not, however, state that this change in absorption profile influences the efficacy of the medicine.


Q: How do I know if the side effects I'm feeling are normal for Vergon?

The official safety profile classifies known adverse effects by frequency (e.g., very common, common). Official patient-focused summaries note that serious adverse reactions, such as an unexplained fever, confusion, or a fast/irregular heartbeat, should prompt contact with a healthcare professional immediately.


Q: If I miss a day of Vergon, what happens?

Regulatory patient guides advise that if a dose is missed, it should be taken as soon as possible, unless it is almost time for the next scheduled dose. In such a situation, the regulatory guidance is that the missed dose should be skipped, and the user should return to their regular schedule without doubling doses.


Q: Is Vergon an antibiotic?

No, Vergon is not an antibiotic. Its regulatory classification defines it as a Phenothiazine Derivative, an Anti-emetic Agent (for nausea and vomiting), and a First-Generation Antipsychotic.


Q: Do I have to take Vergon at a specific time of day?

Standard oral forms of the medicine can generally be taken without specific time constraints. However, certain special forms, such as specific tablets, may have particular instructions, like taking them after meals to help with administration.


Q: Can I drink alcohol while taking Vergon?

Official regulatory documents formally prohibit the co-administration of this drug with large amounts of Central Nervous System (CNS) depressants, and this category includes alcohol. This restriction is due to the risk of intensifying the effects of the CNS depressant.


Q: What should I do if I feel worse after starting Vergon?

If concerning symptoms develop, particularly signs of a serious adverse reaction like an unexplained fever, confusion, or a fast or irregular heartbeat, patient-focused regulatory summaries indicate that contacting a healthcare professional immediately for guidance may be necessary.


Q: What happens if I accidentally take two doses of Vergon?

Regulatory guidance explicitly notes that doses should not be doubled. Taking more than prescribed is associated with the risk of an overdose, which may result in changes in consciousness, severe sleepiness, seizures, or a fast, slow, or irregular heartbeat.


Q: Can Vergon affect my driving ability?

Official product information indicates that this medicine may cause drowsiness and can affect a patient's thinking and movements. Regulatory documents state that users should not drive or operate machinery until they know how the drug affects them.


Q: Is Vergon considered a long-term or short-term treatment?

According to official documents, the drug is used for both types of treatment. For example, it is approved for short-term treatment of conditions like non-psychotic anxiety (with use limited to 12 weeks), and it is also utilized for long-term management of psychotic disorders.


Q: What should I do if I get a rash after taking Vergon?

Itching, rash, redness, or discoloration of the skin are documented as possible adverse reactions to the medication. As with any adverse reaction, official guidance states that any change should be noted and evaluated by a healthcare professional.


Q: Do kids take Vergon, and is the dosage different?

Yes, the medication is approved for use in children aged older than 2 years for specific anti-emetic uses. Official information confirms that pediatric dosing is calculated based on the child's weight, meaning the prescribed amount and frequency is different from adult dosing.


Q: What if Vergon doesn't seem to be working for me after a few weeks?

For certain conditions like psychiatric disorders, regulatory labeling notes that while an initial response is often seen quickly, longer treatment is usually required before the maximal improvement and desired effect are achieved.

How should Vergon be stored and disposed of?

Official Storage and Disposal Requirements

Vergon (Prochlorperazine) must be stored and handled according to the specific instructions provided in the regulatory labeling to maintain product stability and safety.

Storage Scope Mandatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C.
Protection Protect from light and excessive moisture. Do not freeze or store above 30 C.
Container Keep in the original, tight, light-resistant container.
Child Safety Keep out of the sight and reach of children at all times.

Disposal instructions require that unused or expired Vergon be discarded via an official drug take-back program. It is specifically advised not to dispose of the product via wastewater or household waste unless otherwise instructed by a regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vergon found in:

A-Z Index: